Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury

Kidney International

Volumn 90, Issue 1, 2016, Pages 109-122

  Laskowski, Jennifer ^a   Renner, Brandon ^a   Le Quintrec, Moglie ^b   Panzer, Sarah ^c   Hannan, Jonathan P ^a   Ljubanovic, Danica ^d   Ruseva, Marieta M ^e   Borza, Dorin Bogdan ^f   Antonioli, Alexandra H ^a   Pickering, Matthew C ^e   Holers, V Michael ^a   Thurman, Joshua M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d University of Zagreb   (Croatia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

complement; glomerulonephritis; inflammation

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; PROTEIN CRRY; REGULATOR PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT RECEPTOR; CRRY PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FACTOR H GENE; CONTROLLED STUDY; CRRY GENE; GENE MUTATION; GLOMERULOPATHY; KIDNEY INJURY; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RENAL PROTECTION; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; GLOMERULONEPHRITIS; GLOMERULUS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; COMPLEMENT C3; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; GLOMERULONEPHRITIS; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; RECEPTORS, COMPLEMENT;

EID: 84988443352     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.02.036     Document Type: Article

References (54)

1. 1 Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11 (2010), 785–797.
2. 2 Zipfel, P.F., Skerka, C., Complement regulators and inhibitory proteins. Nat Rev Immunol 9 (2009), 729–740.
3. 3 de Cordoba, S.R., de Jorge, E.G., Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151 (2008), 1–13.
4. 4 Pickering, M.C., D'Agati, V.D., Nester, C.M., et al. C3 glomerulopathy: consensus report. Kidney Int 84 (2013), 1079–1089.
5. 5 Servais, A., Fremeaux-Bacchi, V., Lequintrec, M., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44 (2007), 193–199.
6. 6 Servais, A., Noel, L.H., Roumenina, L.T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
7. 7 Martinez-Barricarte, R., Heurich, M., Valdes-Canedo, F., et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120 (2010), 3702–3712.
8. 8 Tortajada, A., Yebenes, H., Abarrategui-Garrido, C., et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123 (2013), 2434–2446.
9. 9 Chen, Q., Wiesener, M., Eberhardt, H.U., et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 124 (2014), 145–155.
10. 10 Zhang, Y., Meyer, N.C., Wang, K., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7 (2012), 265–274.
11. 11 Dragon-Durey, M.A., Fremeaux-Bacchi, V., Loirat, C., et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15 (2004), 787–795.
12. 12 Habbig, S., Mihatsch, M.J., Heinen, S., et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 75 (2009), 1230–1234.
13. 13 Pickering, M.C., Cook, H.T., Warren, J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31 (2002), 424–428.
14. 14 Noris, M., Remuzzi, G., Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 66 (2015), 359–375.
15. 15 Thurman, J.M., Ljubanovic, D., Royer, P.A., et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 116 (2006), 357–368.
16. 16 Renner, B., Coleman, K., Goldberg, R., et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 185 (2010), 3086–3094.
17. 17 Bao, L., Wang, Y., Chang, A., et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 18 (2007), 811–822.
18. 18 Miao, J., Lesher, A.M., Miwa, T., et al. Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury. Kidney Int 86 (2014), 726–737.
19. 19 Ichida, S., Yuzawa, Y., Okada, H., et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46 (1994), 89–96.
20. 20 Xu, C., Mao, D., Holers, V.M., et al. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 287 (2000), 498–501.
21. 21 Walport, M.J., Complement: first of two parts. N Engl J Med 344 (2001), 1058–1066.
22. 22 Fakhouri, F., de Jorge, E.G., Brune, F., et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 78 (2010), 279–286.
23. 23 Thurman, J.M., Kulik, L., Orth, H., et al. Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest 123 (2013), 2218–2230.
24. 24 Pangburn, M.K., Rawal, N., Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 30 (2002), 1006–1010.
25. 25 Paixao-Cavalcante, D., Hanson, S., Botto, M., et al. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol 46 (2009), 1942–1950.
26. 26 Thurman, J.M., Ljubanovic, D., Edelstein, C.L., et al. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 170 (2003), 1517–1523.
27. 27 Wu, X., Spitzer, D., Mao, D., et al. Membrane protein Crry maintains homeostasis of the complement system. J Immunol 181 (2008), 2732–2740.
28. 28 Malik, T.H., Lavin, P.J., Goicoechea de Jorge, E., et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 23 (2012), 1155–1160.
29. 29 Gale, D.P., de Jorge, E.G., Cook, H.T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376 (2010), 794–801.
30. 30 Strobel, S., Zimmering, M., Papp, K., et al. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 47 (2010), 1476–1483.
31. 31 Athanasiou, Y., Voskarides, K., Gale, D.P., et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 6 (2011), 1436–1446.
32. 32 Medjeral-Thomas, N., Malik, T.H., Patel, M.P., et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 85 (2014), 933–937.
33. 33 Thurman, J.M., Royer, P.A., Ljubanovic, D., et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 17 (2006), 707–715.
34. 34 Noris, M., Remuzzi, G., Atypical hemolytic-uremic syndrome. N Engl J Med 361 (2009), 1676–1687.
35. 35 Lenderink, A.M., Liegel, K., Ljubanovic, D., et al. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol 293 (2007), F555–F564.
36. 36 Watanabe, H., Garnier, G., Circolo, A., et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164 (2000), 786–794.
37. 37 Xiao, H., Schreiber, A., Heeringa, P., et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170 (2007), 52–64.
38. 38 Walker, P.D., Ferrario, F., Joh, K., Bonsib, S.M., Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 20 (2007), 605–616.
39. 39 Medjeral-Thomas, N.R., O'Shaughnessy, M.M., O'Regan, J.A., et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 9 (2014), 46–53.
40. 40 Mao, D., Wu, X., Deppong, C., et al. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 19 (2003), 813–822.
41. 41 Ruseva, M.M., Hughes, T.R., Donev, R.M., et al. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Mol Immunol 46 (2009), 803–811.
42. 42 Rose, K.L., Paixao-Cavalcante, D., Fish, J., et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118 (2008), 608–618.
43. 43 Nichols, E.M., Barbour, T.D., Pappworth, I.Y., et al. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int 88 (2015), 1314–1322.
44. 44 Ruseva, M.M., Peng, T., Lasaro, M.A., et al. Efficacy of targeted complement inhibition in experimental C3 glomerulopathy. J Am Soc Nephrol 27 (2016), 405–416.
45. 45 Rother, R.P., Rollins, S.A., Mojcik, C.F., et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25 (2007), 1256–1264.
46. 46 DiLillo, D.J., Pawluczkowycz, A.W., Peng, W., et al. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol Immunol 43 (2006), 1010–1019.
47. 47 Nilsson, S.C., Sim, R.B., Lea, S.M., et al. Complement factor I in health and disease. Mol Immunol 48 (2011), 1611–1620.
48. 48 Barthel, D., Schindler, S., Zipfel, P.F., Plasminogen is a complement inhibitor. J Biol Chem 287 (2012), 18831–18842.
49. 49 Markiewski, M.M., Nilsson, B., Ekdahl, K.N., et al. Complement and coagulation: strangers or partners in crime?. Trends Immunol 28 (2007), 184–192.
50. 50 Frei, Y., Lambris, J.D., Stockinger, B., Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes 1 (1987), 141–149.
51. 51 Summers, S.A., Steinmetz, O.M., Li, M., et al. Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 20 (2009), 2518–2524.
52. 52 Thurman, J.M., Kraus, D.M., Girardi, G., et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 42 (2005), 87–97.
53. 53 Sun, Y., Yu, H., Zheng, D., et al. Sudan black B reduces autofluorescence in murine renal tissue. Arch Pathol Lab Med 135 (2011), 1335–1342.
54. 54 Panzer, S.E., Laskowski, J., Renner, B., et al. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int 88 (2015), 528–537.